Latest News — Page 3

Europe Free account
EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment
The EMA mid-year report 2026 records 485 scientific advice requests in the first half, the first joint clinical assessment under the HTA Regulation and progress on the new pharmaceutical law. #SyenzaNews #MarketAccess

Clinical Practice
Truqap prostate cancer withdrawal: AstraZeneca pulls EU bid
“Truqap prostate cancer withdrawal: AstraZeneca pulled its EU bid for newly diagnosed use after EMA raised benefit-risk concerns.” #SyenzaNews #MarketAccess

Cardiovascular And Metabolic Diseases
Mayo Clinic’s TV question for the home blood pressure monitor
A Mayo Clinic cardiologist’s TV-set question makes the case for a home blood pressure monitor, with a caution on device reliability and home data in the chart.

Cost Effectiveness Analysis Free account
Second Cochlear Implant Now Covered for Adults in the Netherlands
The Dutch health institute Zorginstituut Nederland has concluded that a second cochlear implant for adults with severe hearing loss in both ears belongs in the basic health package. #SyenzaNews #MarketAccess

Clinical Guidelines And Protocols
Global Drug Regulators Summit in Seoul Takes Up AI and Animal Testing Alternatives
The Ministry of Food and Drug Safety hosts ICMRA, the international coalition of medicines regulators, in Seoul from 3 to 6 November 2026, with AI rules and alternatives to animal testing on the agenda. #SyenzaNews #MarketAccess #drugregulation

Clinical Practice Free account
FDA Potency Assurance Guidance: What It Asks of Cell and Gene Therapy Makers
FDA has finalized its potency assurance guidance for cell and gene therapy products. It covers lot-release testing, potency assays, acceptance criteria and how sponsors should build a strategy from the IND stage onward. #SyenzaNews #CellAndGeneTherapy #FDA

Diseases
Generic lenacapavir HIV prevention gets FDA tentative approval
Dr. Reddy’s has FDA tentative approval for generic lenacapavir HIV prevention, priced at US$40 per person per year across 120 countries. #SyenzaNews #HIVprevention #MarketAccess

Asia Free account
PBS Strategic Agreements: What Government and Industry Told Patients Before the Next Deal
Australia’s PBS strategic agreements with the medicines industry expire on 30 June 2027. At a 23 October webinar, the health department, GBMA and Medicines Australia explained what the deals cover, how patients can feed in, and where industry says they have fallen short on access. #SyenzaNews #MarketAccess #HTA #PBS #Australia

Clinical Practice Free account
EMA Opens Deanxit Safety Review Over Movement and Memory Side Effects
EMA’s safety committee has opened a Deanxit safety review at Belgium’s request, after reports of movement disorders and memory problems with the flupentixol/melitracen combination. The Belgian agency also questioned the benefit of combining the two substances. #SyenzaNews #Pharmacovigilance #EMA #MentalHealth

Clinical Practice
FDA Grants Accelerated Approval to Voceryq for Recurrent Respiratory Papillomatosis
The FDA has granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy in the US, for adults with recurrent respiratory papillomatosis.

Clinical Practice Free account
Migraine Medicines in Portugal: Patients Pay 61% of the Outpatient Bill
Infarmed’s first Deep Dive looks at migraine medicines in Portugal. In 2025, more than 73,000 people used SNS-reimbursed migraine therapies, 85% of them women. Patients paid about €6 million (61%) of the €9.9 million pharmacy bill, and atogepant, funded only at the end of 2024, already led spending. #SyenzaNews #Migraine #MarketAccess #Portugal

Innovation
Innovation Growth Theory: Bonvillian on Solow, Romer and Talent
MIT’s William Bonvillian opens his innovation systems course with Solow and Romer: technology drives about two-thirds of US growth, and R&D only pays off with trained talent doing it. His prospector theory has a blunt corollary for anyone fencing off talent. #SyenzaNews #InnovationPolicy #HealthEconomics #RandD

Health Equity And Access To Care Free account
Labor Department Finalizes PBM Fee Disclosure Rule for Large Self-Insured Plans
The US Department of Labor has finalized its PBM fee disclosure rule. From plan years beginning on or after 1 July 2027, PBMs must disclose rebates, spread compensation, copay claw-backs and per-drug net prices to large self-insured ERISA plans, report twice a year, and accept an annual audit by an auditor the plan chooses. EBSA estimates $818.4 million a year in transfers from PBMs to plans and participants. #SyenzaNews #PBM #DrugPricing #MarketAccess

Cardiovascular And Metabolic Diseases
Lancet Authors Make the Case for an EU Medical Device Agency
Four authors writing in The Lancet Regional Health – Europe say the Commission’s MDR and IVDR simplification proposal keeps the core flaw: notified bodies still decide, one by one, whether innovative devices reach the market. They argue for an EU medical device agency with binding powers over strategy, guidance and advice. #SyenzaNews #MedTech #MedicalDevices #MarketAccess

Clinical Practice
Hybrid healthcare hub in Portugal: ULSSM, Medtronic join forces
The Santa Maria Local Health Unit and Medtronic have signed a memorandum to create a hybrid care model that pairs in-person care with remote monitoring. Four clinical areas come first. #SyenzaNews #HealthcareInnovation #DigitalHealth

Clinical Practice
Retatrutide Head-to-Head Trial Shows Greater A1C Cut Than Ozempic
Lilly’s TRANSCEND-T2D-2 trial found retatrutide lowered A1C more than Ozempic 2 mg and produced more than double the weight loss at 80 weeks. #SyenzaNews #clinicaltrials

